Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model
J. Bryan Iorgulescu(Broad Institute), David A. Reardon(Dana-Farber Cancer Institute), Kara M. Soroko(Dana-Farber Cancer Institute), Shanmugarajan Krishnan(University Hospital of Zurich), Ryuhjin Ahn(Allen Institute), Maria C. Speranza(Dana-Farber Cancer Institute), Mario L. Suvà(Broad Institute), Meenal Datta(University of Notre Dame), Benjamin K. Eschle(Dana-Farber Cancer Institute), Raziye Piranlioglu(Brigham and Women's Hospital), E. Antonio Chiocca(Center for Cancer Research), Eleni Panagioti(Beth Israel Deaconess Medical Center), Arlene H. Sharpe(Brigham and Women's Hospital), Catherine J. Wu(Dana-Farber Cancer Institute), Kathleen B. Yates(Broad Institute), Gordon J. Freeman(Dana-Farber Cancer Institute), Prafulla C. Gokhale(Harvard University), Gregory J. Baker(University of California, Los Angeles), Neil Ruthen(Dana-Farber Cancer Institute), Forest M. White(Center for Cancer Research), Martha R. Neagu(Columbia University), Donna Neuberg(Otsuka (Japan))
Cited by 23
Related Papers
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|2.9k
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
|The Journal of Experimental Medicine|2009|2k
Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae
|Nature Biotechnology|2002|1.6k